Related Experiment Video
Updated: Mar 18, 2026
12:42
Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo
Published on: January 7, 2019
10.4K
Oncolytic viral therapy under type I interferon regulation: Mathematical modeling and analysis
Prathibha Ambegoda1, Hsiu-Chuan Wei2, Sophia R-J Jang3
1Department of Mathematics, Stark State College, North Canton, OH, USA.
Mathematical Biosciences
|March 16, 2026
Summary
Oncolytic viral therapy (OVT) efficacy depends on balancing viral infectivity, immune response, and interferon (IFN-I) dynamics. Personalized strategies accounting for these factors are crucial for optimizing OVT outcomes in cancer treatment.
Area of Science:
- Mathematical Biology
- Immunology
- Virology
- Oncology
Background:
- Oncolytic viral therapy (OVT) shows promise for cancer treatment.
- Understanding the complex interplay between tumor cells, the immune system, and viruses is critical for OVT efficacy.
- Type I interferon (IFN-I) signaling plays a significant role in antiviral defense and immune modulation.
Purpose of the Study:
- To develop and analyze a delay differential equation model of OVT.
- To investigate the impact of tumor-immune-virus interactions, IFN-I dynamics, and viral infection cycle delays on treatment outcomes.
- To identify key parameters driving tumor control in OVT.
Main Methods:
- Development of a delay differential equation model.
- Analytical and numerical analysis of the model.
- Bifurcation analysis to study system dynamics.
- Global sensitivity analysis to identify key drivers.
Main Results:
- Treatment efficacy is determined by the balance of viral infectivity, IFN-mediated suppression, and immune recruitment.
- Intracellular delay can destabilize tumor-virus coexistence, while immune responses lead to complex dynamics like bistability.
- IFN production, IFN-induced immune suppression, viral infectivity, and immune proliferation are critical for tumor control.
Conclusions:
- IFN-I has a dual role, potentially promoting viral clearance or persistence, influencing therapeutic outcomes.
- The model highlights the importance of considering IFN signaling, immune status, and viral dynamics for personalized OVT strategies.
- Optimizing OVT requires tailored approaches based on individual patient and viral characteristics.
Related Concept Videos
02:49Cancer Therapies
10.6K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
10.6K
01:27Tumor Immunotherapy
2.1K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.1K
01:15Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
60
PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure...
60
01:51Mechanisms of Retrovirus-induced Cancers
3.0K
3.0K
01:51Mechanisms of Retrovirus-induced Cancers
7.2K
Retroviruses are RNA viruses that have been shown to cause cancers in diverse species, including chickens, mice, cats, and monkeys. The RNA genomes of these viruses are first reverse-transcribed into single and then double-stranded DNA (dsDNA) copies. This dsDNA called proviral DNA then integrates into the host genome. Subsequently, the host cell transcribes the proviral DNA in concert with the chromosomal DNA. This leads to the production of viral RNA and proteins that assemble at the host...
7.2K